These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 30615835)

  • 1. Development of a Convergent Large-Scale Synthesis for Venetoclax, a First-in-Class BCL-2 Selective Inhibitor.
    Ku YY; Chan VS; Christesen A; Grieme T; Mulhern M; Pu YM; Wendt MD
    J Org Chem; 2019 Apr; 84(8):4814-4829. PubMed ID: 30615835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy.
    Li X; Dou J; You Q; Jiang Z
    Eur J Med Chem; 2021 Aug; 220():113539. PubMed ID: 34034128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Covalent Inhibitor That Overcame Resistance to Venetoclax in AML Cells Overexpressing BFL-1.
    Lou J; Zhou Q; Lyu X; Cen X; Liu C; Yan Z; Li Y; Tang H; Liu Q; Ding J; Lu Y; Huang H; Xie H; Zhao Y
    J Med Chem; 2024 Jul; 67(13):10795-10830. PubMed ID: 38913996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca
    Vervloessem T; Ivanova H; Luyten T; Parys JB; Bultynck G
    Biochim Biophys Acta Mol Cell Res; 2017 Jun; 1864(6):968-976. PubMed ID: 27913204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL-2: Long and winding path from discovery to therapeutic target.
    Schenk RL; Strasser A; Dewson G
    Biochem Biophys Res Commun; 2017 Jan; 482(3):459-469. PubMed ID: 28212732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
    Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
    Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax: First Global Approval.
    Deeks ED
    Drugs; 2016 Jun; 76(9):979-87. PubMed ID: 27260335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell- and Tissue-Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin.
    Zhu D; Guo H; Chang Y; Ni Y; Li L; Zhang ZM; Hao P; Xu Y; Ding K; Li Z
    Angew Chem Int Ed Engl; 2018 Jul; 57(30):9284-9289. PubMed ID: 29768700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML.
    Karjalainen R; Liu M; Kumar A; He L; Malani D; Parsons A; Kontro M; Kallioniemi O; Porkka K; Heckman CA
    Leukemia; 2019 Oct; 33(10):2548-2553. PubMed ID: 31175323
    [No Abstract]   [Full Text] [Related]  

  • 10. Venetoclax for the treatment of multiple myeloma.
    Vaxman I; Sidiqi MH; Gertz M
    Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
    [No Abstract]   [Full Text] [Related]  

  • 11. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
    [No Abstract]   [Full Text] [Related]  

  • 12. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.
    Bajpai R; Matulis SM; Wei C; Nooka AK; Von Hollen HE; Lonial S; Boise LH; Shanmugam M
    Oncogene; 2016 Jul; 35(30):3955-64. PubMed ID: 26640142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cancer's Achilles' heel: role of BCL-2 inhibitors in cellular senescence and apoptosis.
    Anantram A; Degani M
    Future Med Chem; 2019 Sep; 11(17):2287-2312. PubMed ID: 31581912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioneering apoptosis-targeted cancer drug poised for FDA approval.
    Mullard A
    Nat Rev Drug Discov; 2016 Mar; 15(3):147-9. PubMed ID: 26931080
    [No Abstract]   [Full Text] [Related]  

  • 16. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
    Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A literature review of the patent publications on venetoclax - a selective Bcl-2 inhibitor: discovering the therapeutic potential of a novel chemotherapeutic agent.
    Žigart N; Časar Z
    Expert Opin Ther Pat; 2019 Jul; 29(7):487-496. PubMed ID: 31154862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
    Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
    Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics.
    Touzeau C; Ryan J; Guerriero J; Moreau P; Chonghaile TN; Le Gouill S; Richardson P; Anderson K; Amiot M; Letai A
    Leukemia; 2016 Mar; 30(3):761-4. PubMed ID: 26174630
    [No Abstract]   [Full Text] [Related]  

  • 20. Forecast: rough seas for leukemia.
    Hockenbery DM
    Cancer Discov; 2014 Mar; 4(3):278-9. PubMed ID: 24596202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.